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Bites and stings
length of 1.25 metres, but may be up to 2
metres long. It has a shiny black dorsal
surface, red or pink lateral scales, and an
underside that is cream, pink or red (Box 1).2
There is limited info mation on the clini-
cal effects of RBBS envenoming3-5 or RBBS








Objective:  To describe the clinical features and laboratory findings in patients with 
definite red-bellied black snake (RBBS; Pseudechis porphyriacus) bites, including 
correlation with results of venom assays.
Design, patients and setting: Prospective cohort study of patients with definite RBBS 
bites, recruited to the Australian Snakebite Project from January 2002 to June 2010.
Main outcome measures: Clinical and laboratory features of envenoming; peak venom 
entrations and antivenom treatment.
lts: There were 81 definite RBBS bites; systemic envenoming occurred in 57 patients 
) and local envenoming alone occurred in one patient. Systemic envenoming was 
cterised by local envenoming in 55 patients (96%), systemic symptoms in 54 patients 
), anticoagulant coagulopathy with a raised activated partial thromboplastin time 
) in 35 patients (61%) and myotoxicity in seven patients (12%). One patient required 
nvasive ventilation for severe myotoxicity that resulted in muscle weakness. Three 
patients developed local ulceration. There were no deaths. Twenty-two envenomed 
patients (39%) received tiger snake or black snake antivenom, and administration within 6 
hours of the bite was associated with normalisation of the aPTT. Eight patients (36%) had 
immediate hypersensitivity reactions to antivenom, including one case of anaphylaxis. The 
median peak venom concentration in 37 systemically envenomed patients with serum 
available was 19ng/mL (interquartile range, 12–50 ng/mL; range, 3–360ng/mL), which did 
not correlate with clinical severity. In 17 patients who received antivenom and had venom 
concentration measured, no venom was detected in serum after the first antivenom dose, 
including nine who were given one vial of tiger snake antivenom.
Conclusion: RBBS envenoming caused local effects, systemic symptoms, anticoagulant 
coagulopathy and, uncommonly, myotoxicity. One vial of tiger snake or black snake 
antivenom appears to be sufficient to remove venom and neutralise reversible effects, but 
MJA 2010; 193: 696–700
hypersensitivity reactions occurred in over a third of patients.he
Ps
caT  red-bellied black snake (RBBS;eudechis porphyriacus) is a frequentuse of snake envenoming in south-
eastern Australia. It inhabits most of the
coastal and mountainous regions of eastern
Australia, extending into parts of South Aus-
tralia.1 The RBBS is an “elapid” snake (mem-
ber of the family Elapidae) with an average
RBBS envenoming syndrome does not pro-
duce systemic coagulopathy or neuropathic
effects.3 The few small series of cases
reported since support this, with only one
report of myotoxicity and only one report of
coagulopathy.3-5,12 RBBS envenoming has
therefore been regarded as not severe and
“only cases with major systemic envenom-
ing should be considered for antivenom
therapy”.13 Initial reports to the Australian
Snakebite Project (ASP) suggested that, in at
least some cases, more significant systemic
effects occurred. Tiger snake antivenom
(TSAV) is recommended for RBBS envenom-
ing, although black snake antivenom
(BlSAV) can also be administered.13
The aims of this study (ASP-11, the 11th
study from the ASP) were to describe the
clinical effects and laboratory features of defi-
nite RBBS envenoming and, where possible,
to correlate peak venom concentrations with
clinical effects and antivenom treatment.
METHODS
We describe a cohort of patients from the
ASP who had definite RBBS bites. The ASP
is an ongoing, multicentre prospective
observational study which recruits patients
with suspected snakebite or snake enven-
oming from over 100 hospitals throughout
Australia. The design of this study has previ-
ously been described in detail,14,15 and
approval was obtained from 19 human
research and ethics committees covering all
institutions involved.
1 Red-bellied black snake (Pseudechis porphyriacus), Megalong Valley, New 
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BITES AN D STINGSAll patients who are recruited to the ASP
have demographic and clinical features,
laboratory results and treatments recorded
on clinical research forms by the treating
health care workers. This information is
then entered into a purpose-built relational
database. Additional serum and citrate
samples are collected from patients
recruited to the ASP; these are centrifuged,
aliquoted, frozen and stored at − 80° C for
analysis of venom and antivenom, and
clotting studies.
A search of the ASP database from January
2002 to June 2010 was performed. Definite
RBBS bites were defined either as expert
identification of the snake or as patient or
non-expert identification of the snake plus a
positive result in the black snake well of the
snake venom detection kit (SVDK). Data
extracted from the ASP database included
age, sex, geographical location, local or sys-
temic clinical effects, laboratory results,
antivenom administration, and other treat-
ments (eg, administration of antiemetics or
analgesics). Clinical systemic envenoming
syndromes were:
• Systemic symptoms — defined as three
or more of nausea, vomiting, headache,
abdominal pain, diarrhoea or diaphoresis.
• Anticoagulant coagulopathy — defined as
an elevated activated partial thromboplastin
time (aPTT), based on the local laboratory
reference range, with a normal fibrinogen. In
patients for whom citrate samples were
stored, clotting studies were repeated.
• Myotoxicity — defined by local or gener-
alised myalgia and/or muscle weakness in
association with a serum creatine kinase
(CK) level > 1000 U/L.
Systemic envenoming was defined as the
presence of any of these three clinical syn-
dromes in patients with a definite RBBS bite.
Local envenoming was defined as local
ulceration, local swelling that persisted for
more than 24 hours, or local pain requiring
analgesia. Non-envenomed patients had nei-
ther local nor systemic envenoming.
Enzyme immunoassay
Venom concentrations were measured using
enzyme immunoassay (EIA) for patients for
whom serum samples were available. The
methods are described in detail else-
where.16,17 In brief, polyclonal antibodies
(IgG) to RBBS were raised in rabbits, conju-
gated to biotin, and used to develop a
sandwich EIA with streptavidin-horseradish
peroxidase as the detecting agent. The limit
of detection of the EIAs was 0.1 ng/mL.
These assays only detect free venom that is
not bound to antivenom. The peak venom
concentration was recorded for each patient.
Statistical analysis
For data that are not normally distributed,
medians, ranges and interquartile ranges
(IQRs) are reported. Proportions are pre-
sented with 95% confidence intervals calcu-
lated using the Wilson’s procedure with a
continuity correction.18 Statistical and
graphical analyses were done in GraphPad
Prism version 5.03 for Windows (GraphPad
Software, San Diego, Calif, USA).
RESULTS
We identified 85 potential cases of RBBS bites
from 873 snakebites in the ASP database for
the period January 2002 to June 2010. Insuf-
ficient data were available for four cases. Of
the remaining 81 patients with definite RBBS
bites, 57 patients (70%) were systemically
envenomed, one had local envenoming alone
and 23 had no evidence of local or systemic
envenoming. Most cases occurred in eastern
New South Wales and south-eastern Queens-
land, two were from Victoria, one from South
Australia and one from the Australian Capital
Territory (Box 2). The median age of patients
with definite RBBS bites was 36 years (IQR,
26–58 years). There were 10 children (12%)
aged under 16 years and 58 male patients
(72%). Box 3 provides details of the patient
demographics and circumstances of the defi-
nite RBBS bites.
Clinical effects and laboratory results
Local envenoming occurred in 55 of the 57
systemically envenomed patients (96%; 95%
CI, 87%–99%) and in one patient without
systemic envenoming, who had swelling and
pain requiring 6 hours of analgesia. Local
ulceration occurred in three systemically
envenomed patients (5%; 95% CI, 1%–16%).
Systemic envenoming was characterised
by systemic symptoms in 54 of 57 patients
(95%; 95% CI, 84%–99%), anticoagulant
coagulopathy with a raised aPTT in 35
patients (61%; 95% CI, 48%–74%) and
myotoxicity in seven patients (12%; 95%
CI, 5%–24%). There were no cases of clini-
cally significant bleeding associated with the
coagulopathy, and no cases of venom-
induced consumption coagulopathy, neuro-
toxicity or thrombotic microangiopathy.
2 Distribution of bites by red-bellied 
black snakes, January 2002 to June 
2010 (n = 81)
3 Patient demographics and circumstances relating to non-envenomed and 
systemically envenomed cases of definite red-bellied black snake bites*
* Data are number (percentage; 95% CI) unless otherwise specified and exclude one patient who was locally 
envenomed only. ◆
Characteristic Non-envenomed Systemically envenomed
Total number of bites 23 57
Median age (range) in years 36 (4–87) 36 (2–83)
Bites to children < 16 years 2 (9%; 2%–30%) 8 (14%; 7%–26%)
Bites to male patients 19 (83%; 60%–94%) 38 (67%; 53%–78%)
Bites to snake handlers 3 (13%; 3%–35%) 10 (18%; 9%–30%)
Upper limb bite 12 (52%; 31%–73%) 31 (54%; 41%–67%)
Pressure immobilisation bandage applied 21 (91%; 70%–98%) 43 (75%; 62%–85%)MJA • Volume 193 Number 11/12 • 6/20 December 2010 697
BITES AN D STINGSOf the seven patients with myotoxicity, all
developed generalised myalgia and one
developed muscle weakness, but ptosis or
descending paralysis did not occur in any of
these patients. Two other patients had a peak
CK level > 1000U/L (1779 U/L and 2723 U/
L) without myalgia or muscle tenderness.
Patients with myotoxicity had a longer
median length of hospital stay than those
systemically envenomed without myotoxicity
(3 days v 21 h), and two of the seven with
myotoxicity required intensive care unit
admission.  A 75-year-old woman with a
peak CK level of 46 900 U/L required non-
invasive ventilation for 24 hours for severe
myotoxicity that resulted in bulbar and inter-
costal muscle weakness which was compli-
cated by pneumonia. A 66-year-old man with
a peak CK level of 56 000 U/L had a creati-
nine level of 151 μmol/L on admission (90
minutes after bite) that peaked at 210 μmol/L
(60 hours after bite), but he did not develop
anuria or other evidence of renal impairment.
There were no deaths. Anosmia was reported
in one patient, but this frequency may be an
underestimate because follow-up of patients
after discharge was rarely possible.
Results from SVDK testing of bite-site
swabs were reported for 63 patients, and
results from SVDK testing of urine were
reported for five patients (four of whom had
bite-site swab SVDK results). In 43 enven-
omed patients with SVDK results, 42 (98%;
95% CI, 86%–100%) had a positive result:
32 positive in the black snake well only
(74%; 95% CI, 59%–86%), eight positive in
black snake and tiger snake wells (19%; 95%
CI, 9%–34%) and two in the tiger snake well
only (5%; 95% CI, 1%–17%). Of the 19 non-
envenomed patients for whom bite-site
SVDK testing was performed, 15 (79%; 95%
CI, 54%–93%) had positive results.
Box 4 shows the time course of the aPTT
for patients given early antivenom ( 6h
after bite), delayed antivenom (> 6 h after
bite) and those not given antivenom. Box 5
shows the time course of the CK levels in
patients with myotoxicity, three of whom
were given antivenom and four of whom
were not given antivenom. Five of the seven
patients with myotoxicity and both patients
with a CK > 1000 U/L and no myalgia had an
early raised aPTT.
Treatment of systemically envenomed 
patients
Antivenom was administered in 22 of the 57
systemically envenomed patients (39%;
95% CI, 26%–52%). Thirteen received one
vial of TSAV, four received two vials of TSAV,
four received one vial of BlSAV (one of
whom was given half the vial only owing to
an adverse reaction) and one received one
vial of polyvalent antivenom. Eight of these
22 patients had an immediate hypersensitiv-
ity reaction to the antivenom; seven had
mild reactions but one had anaphylaxis with
hypotension. The frequency of reactions was
similar for TSAV (6/17) and BlSAV (2/4).
The aPTT appeared to normalise rapidly
with antivenom therapy. Ten patients with a
raised aPTT who were given antivenom  6
hours after the bite had a normal aPTT when
blood was next collected (Box 4, Box 6). Of
seven patients with a raised aPTT who
received antivenom more than 6 hours after
the bite, the aPTT had normalised before
antivenom was given in five (20–32 h after
bite) and aPTT recovered by the time of the
next blood collection in the other two (8.8 h
and 9 h after bite). Raised CK level did not
appear to resolve more rapidly when
antivenom was administered (Box 5). Three
patients with myotoxici ty received
antivenom but were given it 23, 26 and 30
hours after the bite, respectively. The three
patients with local ulceration were given
antivenom at 2.25, 26 and 30 hours after
the bite, respectively, and ulcers were not
noted until more than 24 hours after the
bite. Box 6 shows the clinical features of
patients with anticoagulant coagulopathy
who were given early antivenom ( 6 h after
bite) and patients with anticoagulant coagu-
lopathy who were given delayed antivenom
4 Time course of activated partial 
thromboplastin time (aPTT) for 
patients not given antivenom and 
those given antivenom  6 hours 
or > 6 hours after bite*
* The shaded area indicates the approximate 
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5 Time course of serum creatine kinase levels in patients with myotoxicity, for 
three patients given antivenom and four patients not given antivenom*
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BITES AN D STINGS(> 6 h after bite) or no antivenom. Myotoxic-
ity did not occur in any patients given early
antivenom but occurred in 20% of patients
given no antivenom or delayed antivenom.
Thirty-seven of the 57 systemically enven-
omed patients (65%; 95% CI, 51%–78%)
were treated with antiemetics. Thirty-six
patients received analgesia, 35 of whom had
local envenoming. One child was adminis-
tered morphine by ambulance staff for a
painfully constrictive pressure bandage.
Pain was severe enough to warrant adminis-
tration of opioids in 26 patients.
Venom assays
Serum samples from 47 patients were availa-
ble for testing. Venom was not detected in all
eight non-envenomed patients for whom
samples were available. Of the remaining 39
(who were all systemically envenomed), 22
did not receive antivenom, 15 of those who
received antivenom had post-antivenom
samples, and two of those who received
antivenom had post-antivenom samples only.
The median peak RBBS venom concentration
from the 37 systemically envenomed patients
with more than one serum sample available
was 19 ng/mL (IQR, 12–50 ng/mL; range, 3–
360ng/mL), which did not correlate with
clinical severity (Box 7). The envenomed
patient with a negative SVDK test result had a
peak venom concentration of 50 ng/mL, and
the two envenomed patients with a positive
SVDK result for tiger snake had peak venom
concentrations of 12 ng/mL and 72 ng/mL.
Higher venom concentrations were associ-
ated with antivenom administration but not
with major clinical effects (Box 7). In the 17
patients given antivenom who had venom
concentration measured, no venom was
detected in any blood sample taken after
antivenom was given. Of these 17 patients,
nine received one vial of TSAV, four received
two vials of TSAV and four received at least
one vial of BlSAV.
DISCUSSION
This study has confirmed that RBBS envenom-
ing causes both local and systemic symptoms,
as previously noted. However, in contrast to
previous studies, it shows that the majority of
RBBS envenoming cases develop an anticoagu-
lant coagulopathy characterised by a raised
aPTT, and that a small proportion of patients
develop significant myotoxicity. The results
suggest that the coagulopathy develops within
hours, resolves over about 24 hours in
untreated patients, is not clinically significant
and is rapidly reversed with antivenom admin-
istration. In contrast, myotoxicity develops
slowly and may persist for up to 7 days. It did
not develop in anyone who received early
antivenom, and did not appear to reverse with
antivenom administration. There was poor
correlation between peak venom concentra-
tions and the severity of clinical envenoming
syndromes, but venom was only detected in
the serum of patients with systemic envenom-
ing. One vial of either TSAV or BlSAV was
sufficient to bind all venom. Immediate-type
hypersensitivity reactions occurred in over a
third of antivenom administrations, demon-
strating that antivenom administration is asso-
ciated with significant adverse effects.
Previously, RBBS was thought to cause only
minor effects but this was based on a limited
number of cases. In two small series of 10
and 15 definite cases of RBBS envenoming in
South Australia,4,5 there were 14 cases of
systemic envenoming, but only one patient
had coagulopathy and the remainder only
had systemic symptoms.4,5 A further five
cases again reported only local and systemic
symptoms.3 In contrast to previous studies,
we have shown that an anticoagulant coagu-
lopathy occurred in the majority (61%) of
envenomed patients. However, no patients
developed life-threatening haemorrhage,
which could explain why such a coagu-
lopathy has not been previously recognised.
More concerning was the occurrence of
previously unrecognised significant myotox-
icity in RBBS envenoming. This resulted in
longer hospital stays, admission to intensive
care units and, in one case, assisted ventila-
tion. One patient had an elevated creatinine
level on a background of pre-existing renal
disease. In those with myotoxicity, antivenom
was only administered after the CK was
already high, despite an early abnormal aPTT
in the majority. In contrast, 10 patients with
anticoagulant coagulopathy who received
antivenom 6 hours after the bite had a
rapid normalisation of the aPTT and none
developed myotoxicity. This suggests that it
might be appropriate to administer antivenom
in all patients with a raised aPTT, within 6
hours if possible, to prevent myotoxicity.
Other clinical effects have been reported
with RBBS envenoming including anosmia,3,12
which has also been reported for other black
snake species.19 Anosmia was only reported in
one patient in our study, but patients may only
become aware of it after hospital discharge,
making it easily missed in the acute care
setting. Local envenoming occurred in almost
all cases of RBBS envenoming. Pain relief was
required in about half of envenomed patients,
supporting previous reports that local effects
are an important part of this syndrome.3
6 Clinical features of patients with an anticoagulant coagulopathy — those 
given early antivenom ( 6 hours after bite) versus those given delayed 
(> 6 hours after bite) or no antivenom*†
* Coagulopathy was defined as abnormal activated partial thromboplastin time. † Data are number 
(percentage; 95% CI) unless otherwise specified. ‡ Data are median (interquartile range). ◆
Early antivenom 
(n = 10)
Delayed or no antivenom 
(n = 25)
Myotoxicity 0 5 (20%; 8%–41%)
Serum creatine kinase level > 1000U/L 1 (10%; 1%–46%) 6 (24%; 10%–46%)
Peak serum creatine kinase level (U/L)‡ 337 (236–724) 475 (290–1065)
Systemic symptoms 10 (100%; 66%–100%) 22 (88%; 68%–97%)
Local envenoming 10 (100%; 66%–100%) 23 (92%; 73%–99%)
Local ulceration 1 (10%; 1%–46%) 2 (8%; 1%–28%)
Peak venom concentration (ng/mL)‡ 84 (43–157) 19 (12–45)
7 Peak RBBS venom concentrations in 
patients with major clinical effects 
and those given antivenom*
* Horizontal lines represent median values. 
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BITES AN D STINGSThe poor correlation between venom con-
centrations and the severity of clinical effects
is most likely because the timing of the pre-
antivenom blood collections depended on
when patients presented to hospital. Patients
presenting late will have low venom concen-
trations but be more likely to develop severe
myotoxicity compared with patients present-
ing early, who will have higher venom con-
centrations and may be given antivenom that
prevents myotoxicity. However, there was
good correlation between the detection of
venom in serum and systemic envenoming,
making it a useful confirmatory test of sys-
temic envenoming due to RBBS bite.
Studies of RBBS venom explain the clinical
effects we observed. It is surprising that the
coagulopathy has been under-recognised in
humans. The coagulant effects of the venom
were first recognised over 100 years ago,
when coagulopathy was demonstrated in
dogs injected with venom.20 A prothrombin
activator toxin has been identified in the
venom, but differs to those in other Australa-
sian elapids and its clinical relevance is
unclear.21,22 Although an anticoagulant toxin
has not been isolated, the venom has anti-
coagulant activity based on in vitro clotting
studies.8 The myotoxic effects of RBBS venom
have been demonstrated in vitro and showed
that both TSAV or BlSAV were able to prevent
but not reverse this effect.10
TSAV is currently recommended for RBBS
envenoming,13 which is reflected in it being
the most frequently used antivenom in our
study. It is believed that TSAV is more appro-
priate than BlSAV because it is cheaper and a
lower volume is required. Our study showed
that one vial of TSAV is likely to be sufficient
to bind all venom, with venom undetectable
in all tested patients after administration of
one vial of antivenom. It would appear that
the current recommended dose and type of
antivenom is appropriate for RBBS envenom-
ing, although it possibly should be adminis-
tered earlier and more often than it is in
current practice. However, we did observe
high rates of hypersensitivity reactions to
both TSAV and BlSAV, which need to be
balanced against benefits.
Our study has shown that RBBS envenom-
ing can potentially cause severe effects,
including myotoxicity. An anticoagulant
coagulopathy is common and, although not
clinically significant, the early rise in aPTT
may be a useful indicator of envenoming and
therefore a potential indication for
antivenom. It also supports one vial of TSAV
being enough to bind all venom.
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